EUCTR2005-006066-34-Outside-EU/EEA进行中（未招募）不适用
A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Haemophilus influenzae type b (Hib) control vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age. - Hib-MenCY-TT-011 & Hib-MenCY-TT-012
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 4,429
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects for whom the investigator believes that parents/guardians can and will comply with the requirements of the protocol.
- •A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
- •Written informed consent obtained from the parent or guardian of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Born after 36 weeks gestation.
- •Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment.
- •Infants may have received a birth dose of Bacillus Calmette-Guérin (BCG) vaccine.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 4053
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preced-ing the first dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
- •Planned administration/ administration of a vaccine not fore-seen by the study protocol within 30 days of the first dose of study vaccine(s).
- •Previous vaccination against Neisseria meningitidis, Haemo-philus influenzae type b, diphtheria, tetanus, pertussis, and/or poliovirus; more than one previous dose of hepatitis B vaccine.
- •In country(ies) where Prevnar will be provided by GSK Biologicals, previous vaccination with Prevnar.
- •History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, hepatitis B, and/or poliovirus disease.
- •Any confirmed or suspected immunosuppressive or immuno-deficient condition based on medical history and physical examination.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including dry natural latex rubber.
- •Major congenital defects or serious chronic illness.
- •History of any neurologic disorders or seizures.
- •Acute disease at time of enrollment.
- •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
研究者
相似试验
进行中（未招募）
不适用
A study to compare Pergoveris and GONAL-f in women who have responded poorly to previous infertiliy treatment cyclesPoor Ovarian Response i.e. a failure to respond adequately to standard ART (assisted reproductive technologies) protocols and to recruit adequate folliclesMedDRA version: 17.0Level: LLTClassification code 10033140Term: Ovarian disorder NOSSystem Organ Class: 100000004872EUCTR2013-003817-16-DKMerck KGaA946
进行中（未招募）
不适用
A study to compare Pergoveris and GONAL-f in women who have responded poorly to previous infertiliy treatment cyclesPoor Ovarian Response i.e. a failure to respond adequately to standard ART (assisted reproductive technologies) protocols and to recruit adequate folliclesMedDRA version: 17.1Level: LLTClassification code 10033140Term: Ovarian disorder NOSSystem Organ Class: 100000004872EUCTR2013-003817-16-EEMerck KGaA946
进行中（未招募）
不适用
A study to compare Pergoveris and GONAL-f in women who have responded poorly to previous infertiliy treatment cyclesPoor Ovarian Response i.e. a failure to respond adequately to standard ART (assisted reproductive technologies) protocols and to recruit adequate folliclesMedDRA version: 17.0Level: LLTClassification code 10033140Term: Ovarian disorder NOSSystem Organ Class: 100000004872EUCTR2013-003817-16-LVMerck KGaA946
尚未招募
3 期
A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin alfa) for multifollicular development as part of an assisted reproductive technology treatment cycle in poor ovarian responders, as defined by the European Society of Human Reproduction and Embryology criteriainfertilitypoor ovarian responders10033283NL-OMON40576Merck40
进行中（未招募）
不适用
A study to compare Pergoveris and GONAL-f in women who have responded poorly to previous infertiliy treatment cyclesPoor Ovarian Response i.e. a failure to respond adequately to standard ART (assisted reproductive technologies) protocols and to recruit adequate folliclesMedDRA version: 17.0Level: LLTClassification code 10033140Term: Ovarian disorder NOSSystem Organ Class: 100000004872EUCTR2013-003817-16-NLMerck KGaA946